Abstract
The outbreak of the severe acute respiratory syndrome coronavirus - 2 has quickly turned into a global pandemic. Real-time reverse transcription Polymerase chain reaction is commonly used to diagnose as “gold standard”. Many coronaviruses are sensitive to heat and chemicals. Heat and chemical inactivation of samples is considered a possible method to reduce the risk of transmission, but the effect of heating and chemical treatment on the measurement of the virus is still unclear. Thus, this study aimed to investigate the effect of heat inactivation and chemical bulklysis on virus detection. The laboratory-based experimental study design was conducted in Ethiopian Public Health Institute from August to November 2020 on the samples referred to the laboratory for Coronavirus disease-19 testing. Tests were performed on eighty Nasopharyngeal/Oropharyngeal swab samples using the Abbott Real-time severe acute respiratory syndrome coronavirus - 2 assays, a test for the qualitative detection of virus in the sample. Data were analyzed and described by mean and standard deviation. Repeated measurement analysis of variance was used to assess the mean difference between the three temperatures and bulk lysis on viral detection. Post-hock analysis was employed to locate the place of significant differences. P-values less than 0.05 was used to declare statistical significance. About 6.2% (5/80) of samples were changed to negative results in heat inactivation at 60°C and 8.7% (7/80) of samples were changed to negative in heat inactivation at 100°C. The Cyclic threshold values of heat-inactivated samples (at 60°C, at 100°C, and bulk lysis) were significantly different from the temperature at 56°C. The efficacy of heat-inactivation varies greatly depending on temperature and duration. Therefore, local validation and verification of heat-inactivation are essential.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive ant funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical clearance was obtained from Ethiopian public health institute Scientific ethical review committee. Approval and official permission was obtained from the Ethiopian public health institute research committee to use the leftover samples in the laboratory (EPHI-IRB-296-2020). The confidentiality of the data collected was kept to a maximum and each patient identity was coded.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail address co-authors GG:gadissagutema{at}gmail.com, GGH: kudus12{at}gmail.com RD: regedire{at}gmail.com, GB:gutebdi{at}gmail.com, TS:tolewaks9{at}gmail.com, DA:destaayana185{at}gmail.com, DC: dawitchala2016{at}gmail.com, BL: bokilenjiso{at}gmail.com, JB: jaletatura{at}gmail.com, SA: helen_saro{at}yahoo.com HT:habtetola{at}gmail.com
Data Availability
All data produced in the present work are contained in the manuscript
List of Abbreviations
- CDC
- Center Disease Control and Prevention
- CT
- Cyclic Threshold
- CN
- Cyclic Number
- DNA
- Deoxyribose nucleic acid
- EPHI
- Ethiopian Public Health Institute
- EUA
- Emergency Use Authorization
- IC
- Internal control
- ISO
- International Standard for Organization
- SARS-COV-2
- Severe Acute Respiratory Syndrome Coronavirus 2
- RNA
- Ribonucleic acid
- WHO
- World Health Organization
- RT-PCR
- Real-time Polymerase Chain Reaction
- RdRp
- RNA dependent RNA polymerase
- VTM
- Viral Transport Media